Literature DB >> 24829409

Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.

Hannes Uchtenhagen1, Torben Schiffner2, Emma Bowles3, Leo Heyndrickx4, Celia LaBranche5, Steven E Applequist6, Marianne Jansson7, Thushan De Silva3, Jaap Willem Back8, Adnane Achour1, Gabriella Scarlatti9, Anders Fomsgaard10, David Montefiori5, Guillaume Stewart-Jones3, Anna-Lena Spetz11.   

Abstract

Our knowledge of the binding sites for neutralizing Abs (NAb) that recognize a broad range of HIV-1 strains (bNAb) has substantially increased in recent years. However, gaps remain in our understanding of how to focus B cell responses to vulnerable conserved sites within the HIV-1 envelope glycoprotein (Env). In this article, we report an immunization strategy composed of a trivalent HIV-1 (clade B envs) DNA prime, followed by a SIVmac239 gp140 Env protein boost that aimed to focus the immune response to structurally conserved parts of the HIV-1 and simian immunodeficiency virus (SIV) Envs. Heterologous NAb titers, primarily to tier 1 HIV-1 isolates, elicited during the trivalent HIV-1 env prime, were significantly increased by the SIVmac239 gp140 protein boost in rabbits. Epitope mapping of Ab-binding reactivity revealed preferential recognition of the C1, C2, V2, V3, and V5 regions. These results provide a proof of concept that a distally related retroviral SIV Env protein boost can increase pre-existing NAb responses against HIV-1.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24829409      PMCID: PMC4112278          DOI: 10.4049/jimmunol.1301898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  AIDS/HIV. A boost for HIV vaccine design.

Authors:  Dennis R Burton; Robin A Weiss
Journal:  Science       Date:  2010-08-13       Impact factor: 47.728

2.  Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.

Authors:  Sushil Kumar Pathak; Annette E Sköld; Venkatramanan Mohanram; Catrine Persson; Ulrika Johansson; Anna-Lena Spetz
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

Review 3.  DNA vaccines: an historical perspective and view to the future.

Authors:  Margaret A Liu
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells.

Authors:  Anna-Lena Spetz; Anna Smed Sörensen; Lilian Walther-Jallow; Britta Wahren; Jan Andersson; Lars Holmgren; Jorma Hinkula
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Authors:  Punnee Pitisuttithum; Sorachai Nitayaphan; Prasert Thongcharoen; Chirasak Khamboonruang; Jerome Kim; Mark de Souza; Thippawan Chuenchitra; Robin P Garner; Darawan Thapinta; Victoria Polonis; Silvia Ratto-Kim; Penprapa Chanbancherd; Joseph Chiu; Deborah L Birx; Anne-Marie Duliege; John G McNeil; Arthur E Brown
Journal:  J Infect Dis       Date:  2003-07-03       Impact factor: 5.226

7.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

8.  Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Authors:  Leo Heyndrickx; Guillaume Stewart-Jones; Marianne Jansson; Hanneke Schuitemaker; Emma Bowles; Luigi Buonaguro; Berit Grevstad; Lasse Vinner; Katleen Vereecken; Joe Parker; Meghna Ramaswamy; Priscilla Biswas; Guido Vanham; Gabriella Scarlatti; Anders Fomsgaard
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

9.  Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Florian Klein; Michael S Seaman; Mila Jankovic; Davide Corti; Antonio Lanzavecchia; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

10.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

View more
  1 in total

1.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Authors:  Rogier W Sanders; Marit J van Gils; Ronald Derking; Devin Sok; Thomas J Ketas; Judith A Burger; Gabriel Ozorowski; Albert Cupo; Cassandra Simonich; Leslie Goo; Heather Arendt; Helen J Kim; Jeong Hyun Lee; Pavel Pugach; Melissa Williams; Gargi Debnath; Brian Moldt; Mariëlle J van Breemen; Gözde Isik; Max Medina-Ramírez; Jaap Willem Back; Wayne C Koff; Jean-Philippe Julien; Eva G Rakasz; Michael S Seaman; Miklos Guttman; Kelly K Lee; Per Johan Klasse; Celia LaBranche; William R Schief; Ian A Wilson; Julie Overbaugh; Dennis R Burton; Andrew B Ward; David C Montefiori; Hansi Dean; John P Moore
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.